. 2019 Mar; 10:292.
doi: 10.3389/fimmu.2019.00292.

FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy

Xin Chen 1 Xiaomin Song 1 Kang Li 1 Tong Zhang 1 
  • PMID: 30863404
  •     154 References
  •     45 citations


T cells play critical roles in anti-tumor immunity. Up-regulation of immune checkpoint molecules (PD-1, PD-L1, CTLA-4, TIM-3, Lag-3, TIGIT, CD73, VISTA, B7-H3) in the tumor microenvironment is an important mechanism that restrains effector T cells from the anti-tumor activity. To date, immune checkpoint antibodies have demonstrated significant clinical benefits for cancer patients treated with mono- or combination immunotherapies. However, many tumors do not respond to the treatment well, and merely blocking the immune suppression pathways by checkpoint-regulatory antibodies may not render optimal tumor growth inhibition. Binding of the antibody Fc-hinge region to Fc gamma receptors (FcγRs) has been shown to exert a profound impact on antibody function and in vivo efficacy. Investigation of immune checkpoint antibodies regarding their effector functions and impact on therapeutic efficacy has gained more attention in recent years. In this review, we discuss Fc variants of antibodies against immune checkpoint targets and the potential mechanisms of how FcγR-binding could influence the anti-tumor activity of these antibodies.

Keywords: FcγR; IgG isotype; antibody therapy; cancer immunotherapy; checkpoint blockade.

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H Nishimura, M Nose, +2 authors, T Honjo.
Immunity, 1999 Sep 15; 11(2). PMID: 10485649
Highly Cited.
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
H Dong, G Zhu, K Tamada, L Chen.
Nat Med, 1999 Dec 02; 5(12). PMID: 10581077
Highly Cited.
In vitro characterization of five humanized OKT3 effector function variant antibodies.
D Xu, M L Alegre, +9 authors, R A Zivin.
Cell Immunol, 2000 Mar 16; 200(1). PMID: 10716879
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
R A Clynes, T L Towers, L G Presta, J V Ravetch.
Nat Med, 2000 Mar 31; 6(4). PMID: 10742152
Highly Cited.
The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A.
B D Wines, M S Powell, +2 authors, P M Hogarth.
J Immunol, 2000 May 09; 164(10). PMID: 10799893
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.
R L Shields, A K Namenuk, +9 authors, L G Presta.
J Biol Chem, 2000 Nov 30; 276(9). PMID: 11096108
Highly Cited.
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Y Latchman, C R Wood, +18 authors, G J Freeman.
Nat Immunol, 2001 Feb 27; 2(3). PMID: 11224527
Highly Cited.
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.
A I Chapoval, J Ni, +8 authors, L Chen.
Nat Immunol, 2001 Feb 27; 2(3). PMID: 11224528
Highly Cited.
IgG4 breaking the rules.
Rob C Aalberse, Janine Schuurman.
Immunology, 2002 Feb 19; 105(1). PMID: 11849310    Free PMC article.
Highly Cited. Review.
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.
A Ioan-Facsinay, S J de Kimpe, +18 authors, J S Verbeek.
Immunity, 2002 Mar 26; 16(3). PMID: 11911824
B7 family molecules: novel immunomodulators at the maternal-fetal interface.
M G Petroff, L Chen, T A Phillips, J S Hunt.
Placenta, 2002 Apr 30; 23 Suppl A. PMID: 11978065
Characterization of mouse and human B7-H3 genes.
Mingyi Sun, Sabrina Richards, +3 authors, Chen Dong.
J Immunol, 2002 Jun 11; 168(12). PMID: 12055244
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
Cristina Bottino, Roberta Castriconi, +11 authors, Alessandro Moretta.
J Exp Med, 2003 Aug 13; 198(4). PMID: 12913096    Free PMC article.
Highly Cited.
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y Ishida, Y Agata, K Shibahara, T Honjo.
EMBO J, 1992 Nov 01; 11(11). PMID: 1396582    Free PMC article.
Highly Cited.
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance.
Catherine A Sabatos, Sumone Chakravarti, +7 authors, Vijay K Kuchroo.
Nat Immunol, 2003 Oct 14; 4(11). PMID: 14556006
Highly Cited.
Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo.
Creg J Workman, Linda S Cauley, +3 authors, Dario A A Vignali.
J Immunol, 2004 Apr 22; 172(9). PMID: 15100286
Murine B7-H3 is a negative regulator of T cells.
Durbaka V R Prasad, Thang Nguyen, +4 authors, Chen Dong.
J Immunol, 2004 Aug 06; 173(4). PMID: 15294965
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.
Tsvetelina Pentcheva-Hoang, Jackson G Egen, Kathleen Wojnoonski, James P Allison.
Immunity, 2004 Sep 11; 21(3). PMID: 15357951
Highly Cited.
Role of LAG-3 in regulatory T cells.
Ching-Tai Huang, Creg J Workman, +11 authors, Dario A A Vignali.
Immunity, 2004 Oct 16; 21(4). PMID: 15485628
Highly Cited.
A theoretical framework for quantitative analysis of the molecular basis of costimulation.
Andreas Jansson, Eleanor Barnes, +4 authors, Patric Nilsson.
J Immunol, 2005 Jul 22; 175(3). PMID: 16034096
FcgammaRIV: a novel FcR with distinct IgG subclass specificity.
Falk Nimmerjahn, Pierre Bruhns, Ken Horiuchi, Jeffrey V Ravetch.
Immunity, 2005 Jul 26; 23(1). PMID: 16039578
Highly Cited.
FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling.
Hajime Kono, Chieko Kyogoku, +5 authors, Zen-Ichiro Honda.
Hum Mol Genet, 2005 Aug 24; 14(19). PMID: 16115811
A molecular perspective of CTLA-4 function.
Wendy A Teft, Mark G Kirchhof, Joaquín Madrenas.
Annu Rev Immunol, 2006 Mar 23; 24. PMID: 16551244
Highly Cited. Review.
B7-H3 and B7-H4 expression in non-small-cell lung cancer.
Yuping Sun, Yunshan Wang, +4 authors, Xiongbiao Wang.
Lung Cancer, 2006 Jun 20; 53(2). PMID: 16782226
Highly Cited.
LAG-3, a novel lymphocyte activation gene closely related to CD4.
F Triebel, S Jitsukawa, +4 authors, T Hercend.
J Exp Med, 1990 May 01; 171(5). PMID: 1692078    Free PMC article.
Highly Cited.
TIM-3 in autoimmunity.
Ana C Anderson, David E Anderson.
Curr Opin Immunol, 2006 Oct 03; 18(6). PMID: 17011764
B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.
Junko Hori, Mingcong Wang, +6 authors, Miyuki Azuma.
J Immunol, 2006 Oct 24; 177(9). PMID: 17056517
Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria.
Menna R Clatworthy, Lisa Willcocks, +6 authors, Kenneth G C Smith.
Proc Natl Acad Sci U S A, 2007 Apr 17; 104(17). PMID: 17435165    Free PMC article.
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
Timothy J Roth, Yuri Sheinin, +10 authors, Eugene D Kwon.
Cancer Res, 2007 Aug 10; 67(16). PMID: 17686830
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.
Joseph F Grosso, Cristin C Kelleher, +10 authors, Charles G Drake.
J Clin Invest, 2007 Oct 13; 117(11). PMID: 17932562    Free PMC article.
Highly Cited.
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
Xingxing Zang, R Houston Thompson, +6 authors, James P Allison.
Proc Natl Acad Sci U S A, 2007 Nov 29; 104(49). PMID: 18042703    Free PMC article.
Highly Cited.
Fcgamma receptors as regulators of immune responses.
Falk Nimmerjahn, Jeffrey V Ravetch.
Nat Rev Immunol, 2007 Dec 08; 8(1). PMID: 18064051
Highly Cited. Review.
PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes.
M R Clark, S G Stuart, +2 authors, I M Goldstein.
Eur J Immunol, 1991 Aug 01; 21(8). PMID: 1831131
Human IgG2 antibodies display disulfide-mediated structural isoforms.
Jette Wypych, Ming Li, +11 authors, Alain Balland.
J Biol Chem, 2008 Mar 15; 283(23). PMID: 18339624    Free PMC article.
Structural and functional characterization of disulfide isoforms of the human IgG2 subclass.
Thomas M Dillon, Margaret Speed Ricci, +11 authors, Pavel V Bondarenko.
J Biol Chem, 2008 Mar 15; 283(23). PMID: 18339626    Free PMC article.
Structural characterization of a human Fc fragment engineered for lack of effector functions.
Vaheh Oganesyan, Changshou Gao, +2 authors, William F Dall'Acqua.
Acta Crystallogr D Biol Crystallogr, 2008 Jun 19; 64(Pt 6). PMID: 18560159    Free PMC article.
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
Paul L Crispen, Yuri Sheinin, +9 authors, Eugene D Kwon.
Clin Cancer Res, 2008 Aug 13; 14(16). PMID: 18694993    Free PMC article.
Human IgG2 antibody disulfide rearrangement in vivo.
Y Diana Liu, Xiaoyu Chen, +3 authors, Gregory C Flynn.
J Biol Chem, 2008 Aug 21; 283(43). PMID: 18713741    Free PMC article.
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Chrysoula I Liakou, Ashish Kamat, +5 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2008 Sep 27; 105(39). PMID: 18818309    Free PMC article.
Highly Cited.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions.
Lucie Baudino, Yasuro Shinohara, +7 authors, Shozo Izui.
J Immunol, 2008 Oct 23; 181(9). PMID: 18941257
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.
Xin Yu, Kristin Harden, +9 authors, Jane L Grogan.
Nat Immunol, 2008 Nov 18; 10(1). PMID: 19011627
Highly Cited.
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.
Pierre Bruhns, Bruno Iannascoli, +4 authors, Marc Daëron.
Blood, 2008 Nov 20; 113(16). PMID: 19018092
Highly Cited.
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC.
Kent S Boles, William Vermi, +5 authors, Marco Colonna.
Eur J Immunol, 2009 Feb 07; 39(3). PMID: 19197944    Free PMC article.
Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.
Javier G Casado, Graham Pawelec, +6 authors, Raquel Tarazona.
Cancer Immunol Immunother, 2009 Mar 05; 58(9). PMID: 19259667
Diagnosis value of serum B7-H3 expression in non-small cell lung cancer.
Guangbo Zhang, Yuehua Xu, +4 authors, Xueguang Zhang.
Lung Cancer, 2009 Mar 10; 66(2). PMID: 19269710
PD-1 on dendritic cells impedes innate immunity against bacterial infection.
Sheng Yao, Shengdian Wang, +9 authors, Lieping Chen.
Blood, 2009 Apr 03; 113(23). PMID: 19339692    Free PMC article.
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Mojgan Ahmadzadeh, Laura A Johnson, +4 authors, Steven A Rosenberg.
Blood, 2009 May 09; 114(8). PMID: 19423728    Free PMC article.
Highly Cited.
Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.
Lucy Golden-Mason, Brent E Palmer, +7 authors, Hugo R Rosen.
J Virol, 2009 Jul 10; 83(18). PMID: 19587053    Free PMC article.
Highly Cited.
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.
Aran F Labrijn, Antonio Ortiz Buijsse, +9 authors, Paul W H I Parren.
Nat Biotechnol, 2009 Jul 22; 27(8). PMID: 19620983
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.
Noa Stanietsky, Hrvoje Simic, +11 authors, Ofer Mandelboim.
Proc Natl Acad Sci U S A, 2009 Oct 10; 106(42). PMID: 19815499    Free PMC article.
Highly Cited.
IgG2m4, an engineered antibody isotype with reduced Fc function.
Zhiqiang An, Gail Forrest, +13 authors, William Strohl.
MAbs, 2010 Jan 16; 1(6). PMID: 20073128    Free PMC article.
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.
Elias A Said, Franck P Dupuy, +16 authors, Rafick-Pierre Sekaly.
Nat Med, 2010 Mar 09; 16(4). PMID: 20208540    Free PMC article.
Highly Cited.
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Junko Matsuzaki, Sacha Gnjatic, +9 authors, Kunle Odunsi.
Proc Natl Acad Sci U S A, 2010 Apr 14; 107(17). PMID: 20385810    Free PMC article.
Highly Cited.
Therapeutic antibodies for autoimmunity and inflammation.
Andrew C Chan, Paul J Carter.
Nat Rev Immunol, 2010 Apr 24; 10(5). PMID: 20414204
Highly Cited. Review.
FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.
Kenneth G C Smith, Menna R Clatworthy.
Nat Rev Immunol, 2010 Apr 24; 10(5). PMID: 20414206    Free PMC article.
Highly Cited. Review.
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.
Xingxing Zang, Peggy S Sullivan, +10 authors, James P Allison.
Mod Pathol, 2010 May 25; 23(8). PMID: 20495537    Free PMC article.
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Julien Fourcade, Zhaojun Sun, +6 authors, Hassane M Zarour.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819923    Free PMC article.
Highly Cited.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, +3 authors, Ana C Anderson.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819927    Free PMC article.
Highly Cited.
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.
Falk Nimmerjahn, Anja Lux, +5 authors, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2010 Oct 27; 107(45). PMID: 20974962    Free PMC article.
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice.
Taku Okazaki, Il-mi Okazaki, +9 authors, Tasuku Honjo.
J Exp Med, 2011 Feb 09; 208(2). PMID: 21300912    Free PMC article.
Vstm3 is a member of the CD28 family and an important modulator of T-cell function.
Steven D Levin, David W Taft, +21 authors, Katherine E Lewis.
Eur J Immunol, 2011 Mar 19; 41(4). PMID: 21416464    Free PMC article.
Characterization of soluble vs membrane-bound human placental 5'-nucleotidase.
M R Klemens, W R Sherman, +3 authors, L F Thompson.
Biochem Biophys Res Commun, 1990 Nov 15; 172(3). PMID: 2173922
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, +18 authors, Dario A A Vignali.
Cancer Res, 2011 Dec 22; 72(4). PMID: 22186141    Free PMC article.
Highly Cited.
High expression of CD73 as a poor prognostic biomarker in human colorectal cancer.
Xian-Rui Wu, Xiao-Sheng He, +7 authors, Ping Lan.
J Surg Oncol, 2012 Jan 31; 106(2). PMID: 22287455
Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function.
Hongcheng Liu, Kimberly May.
MAbs, 2012 Feb 14; 4(1). PMID: 22327427    Free PMC article.
Highly Cited. Review.
TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Xin Gao, Yibei Zhu, +7 authors, Binfeng Lu.
PLoS One, 2012 Mar 01; 7(2). PMID: 22363469    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Hang Li, Ke Wu, +8 authors, Weiping Zou.
Hepatology, 2012 Apr 17; 56(4). PMID: 22505239
Highly Cited.
Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.
Xuewei Zhuang, Xiaoning Zhang, +5 authors, Chunhong Ma.
Am J Clin Pathol, 2012 May 16; 137(6). PMID: 22586058
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Deryk Loo, Ralph F Alderson, +21 authors, Paul A Moore.
Clin Cancer Res, 2012 May 23; 18(14). PMID: 22615450
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
Fubin Li, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2012 Jun 23; 109(27). PMID: 22723355    Free PMC article.
FcγRIIb on liver sinusoidal endothelium clears small immune complexes.
Latha P Ganesan, Jonghan Kim, +5 authors, Clark L Anderson.
J Immunol, 2012 Oct 12; 189(10). PMID: 23053513    Free PMC article.
The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy.
David A Mancardi, Marcello Albanesi, +6 authors, Pierre Bruhns.
Blood, 2013 Jan 08; 121(9). PMID: 23293080
Tim-3 expression defines regulatory T cells in human tumors.
Jing Yan, Yi Zhang, +3 authors, Limin Zheng.
PLoS One, 2013 Mar 26; 8(3). PMID: 23526963    Free PMC article.
Structure and T cell inhibition properties of B7 family member, B7-H3.
Vladimir Vigdorovich, Udupi A Ramagopal, +6 authors, Steven C Almo.
Structure, 2013 Apr 16; 21(5). PMID: 23583036    Free PMC article.
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
Sherene Loi, Sandra Pommey, +4 authors, John Stagg.
Proc Natl Acad Sci U S A, 2013 Jun 19; 110(27). PMID: 23776241    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.
Fubin Li, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2013 Nov 13; 110(48). PMID: 24218606    Free PMC article.
Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads.
Kirsten K Dietze, Gennadiy Zelinskyy, +3 authors, Ulf Dittmer.
PLoS Pathog, 2013 Dec 18; 9(12). PMID: 24339778    Free PMC article.
Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer.
Jing Jiang, Mei-Shan Jin, +6 authors, Xueyuan Cao.
PLoS One, 2013 Dec 18; 8(12). PMID: 24339967    Free PMC article.
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
Alena Gros, Paul F Robbins, +13 authors, Steven A Rosenberg.
J Clin Invest, 2014 Mar 29; 124(5). PMID: 24667641    Free PMC article.
Highly Cited.
VISTA is an immune checkpoint molecule for human T cells.
J Louise Lines, Eirini Pantazi, +8 authors, Randolph Noelle.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691993    Free PMC article.
Highly Cited.
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
Nicole Joller, Ester Lozano, +13 authors, Vijay K Kuchroo.
Immunity, 2014 Apr 22; 40(4). PMID: 24745333    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
PD-1 as an immune modulatory receptor.
Sheng Yao, Lieping Chen.
Cancer J, 2014 Aug 08; 20(4). PMID: 25098286    Free PMC article.
The roles of CD73 in cancer.
Zhao-wei Gao, Ke Dong, Hui-zhong Zhang.
Biomed Res Int, 2014 Aug 16; 2014. PMID: 25126561    Free PMC article.
IgG subclasses and allotypes: from structure to effector functions.
Gestur Vidarsson, Gillian Dekkers, Theo Rispens.
Front Immunol, 2014 Nov 05; 5. PMID: 25368619    Free PMC article.
Highly Cited. Review.
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J Johnston, Laetitia Comps-Agrar, +9 authors, Jane L Grogan.
Cancer Cell, 2014 Dec 04; 26(6). PMID: 25465800
Highly Cited.
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
Ann L White, H T Claude Chan, +15 authors, Martin J Glennie.
Cancer Cell, 2014 Dec 17; 27(1). PMID: 25500122    Free PMC article.
Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding.
Jinghua Lu, Jonathan Chu, +3 authors, Peter D Sun.
Proc Natl Acad Sci U S A, 2015 Jan 07; 112(3). PMID: 25561553    Free PMC article.
Confusing signals: recent progress in CTLA-4 biology.
Lucy S K Walker, David M Sansom.
Trends Immunol, 2015 Jan 15; 36(2). PMID: 25582039    Free PMC article.
Highly Cited. Review.
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells.
Theodore Kouo, Lanqing Huang, +4 authors, Elizabeth Jaffee.
Cancer Immunol Res, 2015 Feb 19; 3(4). PMID: 25691328    Free PMC article.
Highly Cited.
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock.
Mol Cancer Ther, 2015 Feb 20; 14(4). PMID: 25695955
Highly Cited. Review.
The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.
Yoshihiro Komohara, Tomoko Morita, +11 authors, Masahisa Jinushi.
Cancer Immunol Res, 2015 Mar 19; 3(9). PMID: 25783986
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, +8 authors, Hassane M Zarour.
J Clin Invest, 2015 Apr 14; 125(5). PMID: 25866972    Free PMC article.
Highly Cited.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Jun Liu, Ying Yuan, +8 authors, Li Wang.
Proc Natl Acad Sci U S A, 2015 May 13; 112(21). PMID: 25964334    Free PMC article.
Highly Cited.
PD-L1 blockade for cancer treatment: MEDI4736.
Ramy Ibrahim, Ross Stewart, Aiman Shalabi.
Semin Oncol, 2015 May 13; 42(3). PMID: 25965366
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Benjamin Boyerinas, Caroline Jochems, +4 authors, Jeffrey Schlom.
Cancer Immunol Res, 2015 May 28; 3(10). PMID: 26014098    Free PMC article.
Highly Cited.
CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer.
Bruno G Leclerc, Roxanne Charlebois, +4 authors, John Stagg.
Clin Cancer Res, 2015 Aug 09; 22(1). PMID: 26253870
Comprehensive Analysis of the Therapeutic IgG4 Antibody Pembrolizumab: Hinge Modification Blocks Half Molecule Exchange In Vitro and In Vivo.
Xiaoyu Yang, Fengqiang Wang, +12 authors, Alexandre Ambrogelly.
J Pharm Sci, 2015 Aug 27; 104(12). PMID: 26308749
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
Rony Dahan, Emanuela Sega, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2015 Sep 17; 28(3). PMID: 26373277
Highly Cited.
TIGIT predominantly regulates the immune response via regulatory T cells.
Sema Kurtulus, Kaori Sakuishi, +6 authors, Ana C Anderson.
J Clin Invest, 2015 Sep 29; 125(11). PMID: 26413872    Free PMC article.
Highly Cited.
The many faces of FcγRI: implications for therapeutic antibody function.
Jennifer F A Swisher, Gerald M Feldman.
Immunol Rev, 2015 Oct 27; 268(1). PMID: 26497519
Influence of immunoglobulin isotype on therapeutic antibody function.
Stephen A Beers, Martin J Glennie, Ann L White.
Blood, 2016 Jan 15; 127(9). PMID: 26764357    Free PMC article.
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.
James C Geoghegan, Gundo Diedrich, +5 authors, Melissa M Damschroder.
MAbs, 2016 Feb 09; 8(3). PMID: 26854859    Free PMC article.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, +23 authors, Peter S Hammerman.
Nat Commun, 2016 Feb 18; 7. PMID: 26883990    Free PMC article.
Highly Cited.
Immunoglobulin isotype knowledge and application to Fc engineering.
Randall J Brezski, George Georgiou.
Curr Opin Immunol, 2016 Mar 24; 40. PMID: 27003675
Anti-CD73 in cancer immunotherapy: awakening new opportunities.
Luca Antonioli, Gennady G Yegutkin, +2 authors, György Haskó.
Trends Cancer, 2016 Mar 26; 2(2). PMID: 27014745    Free PMC article.
Highly Cited.
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Ana C Anderson, Nicole Joller, Vijay K Kuchroo.
Immunity, 2016 May 19; 44(5). PMID: 27192565    Free PMC article.
Highly Cited. Review.
CD73-adenosine reduces immune responses and survival in ovarian cancer patients.
Pierre-Olivier Gaudreau, Bertrand Allard, Martin Turcotte, John Stagg.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467942    Free PMC article.
CD73 is associated with poor prognosis in HNSCC.
Zhen-Hu Ren, Cheng-Zhong Lin, +12 authors, Chen-Ping Zhang.
Oncotarget, 2016 Aug 25; 7(38). PMID: 27557512    Free PMC article.
Targeting CD73 in the tumor microenvironment with MEDI9447.
Carl M Hay, Erin Sult, +15 authors, Kris F Sachsenmeier.
Oncoimmunology, 2016 Sep 14; 5(8). PMID: 27622077    Free PMC article.
Highly Cited.
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Stéphane Champiat, Laurent Dercle, +8 authors, Charles Ferté.
Clin Cancer Res, 2016 Nov 09; 23(8). PMID: 27827313
Highly Cited.
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
Brant A Inman, Thomas A Longo, Sundhar Ramalingam, Michael R Harrison.
Clin Cancer Res, 2016 Dec 03; 23(8). PMID: 27903674
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Yusuke Inoue, Katsuhiro Yoshimura, +10 authors, Haruhiko Sugimura.
Oncotarget, 2017 Jan 07; 8(5). PMID: 28060732    Free PMC article.
Highly Cited.
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.
Gulidanna Shayan, Raghvendra Srivastava, +3 authors, Robert L Ferris.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197389    Free PMC article.
Highly Cited.
CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity.
Zhao-Wei Gao, Hui-Ping Wang, +4 authors, Ke Dong.
BMC Cancer, 2017 Feb 17; 17(1). PMID: 28202050    Free PMC article.
Tim-3 and its role in regulating anti-tumor immunity.
Madhumita Das, Chen Zhu, Vijay K Kuchroo.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258697    Free PMC article.
Highly Cited. Review.
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
Steven Seaman, Zhongyu Zhu, +24 authors, Brad St Croix.
Cancer Cell, 2017 Apr 12; 31(4). PMID: 28399408    Free PMC article.
Highly Cited.
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
E Saâda-Bouzid, C Defaucheux, +11 authors, C Le Tourneau.
Ann Oncol, 2017 Apr 19; 28(7). PMID: 28419181
Highly Cited.
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
Sean P Arlauckas, Christopher S Garris, +9 authors, Mikael J Pittet.
Sci Transl Med, 2017 May 12; 9(389). PMID: 28490665    Free PMC article.
Highly Cited.
Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.
Dipti Vijayan, Deborah S Barkauskas, +7 authors, Mark J Smyth.
Oncoimmunology, 2017 Jun 24; 6(5). PMID: 28638737    Free PMC article.
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Young-Hee Lee, Natalia Martin-Orozco, +23 authors, Chen Dong.
Cell Res, 2017 Jul 08; 27(8). PMID: 28685773    Free PMC article.
Highly Cited.
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
Rony Dahan, Emanuela Sega, +3 authors, Jeffrey V Ravetch.
Cancer Cell, 2015 Oct 12; 28(4). PMID: 28854351
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.
Silvana Morello, Mariaelena Capone, +6 authors, Paolo Antonio Ascierto.
J Transl Med, 2017 Dec 06; 15(1). PMID: 29202855    Free PMC article.
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia.
J Immunother Cancer, 2018 Jan 24; 6(1). PMID: 29357948    Free PMC article.
Highly Cited. Review.
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Xuexiang Du, Mingyue Liu, +8 authors, Pan Zheng.
Cell Res, 2018 Feb 22; 28(4). PMID: 29463898    Free PMC article.
Highly Cited.
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Xuexiang Du, Fei Tang, +14 authors, Yang Liu.
Cell Res, 2018 Feb 24; 28(4). PMID: 29472691    Free PMC article.
Highly Cited.
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Julian A Marin-Acevedo, Bhagirathbhai Dholaria, +3 authors, Yanyan Lou.
J Hematol Oncol, 2018 Mar 17; 11(1). PMID: 29544515    Free PMC article.
Highly Cited. Review.
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Michael D Oberst, Catherine Augé, +19 authors, Scott A Hammond.
Mol Cancer Ther, 2018 Mar 17; 17(5). PMID: 29545330    Free PMC article.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, +30 authors, CheckMate 214 Investigators.
N Engl J Med, 2018 Mar 22; 378(14). PMID: 29562145    Free PMC article.
Highly Cited.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, +21 authors, Luis Paz-Ares.
N Engl J Med, 2018 Apr 17; 378(22). PMID: 29658845    Free PMC article.
Highly Cited.
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
Tong Zhang, Xiaomin Song, +20 authors, Kang Li.
Cancer Immunol Immunother, 2018 Apr 25; 67(7). PMID: 29687231    Free PMC article.
Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI.
Arianne M Brandsma, Samantha L Schwartz, +7 authors, Jeanette H W Leusen.
Sci Signal, 2018 Jul 26; 11(540). PMID: 30042128    Free PMC article.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Anu Sharma, Sumit K Subudhi, +6 authors, Padmanee Sharma.
Clin Cancer Res, 2018 Jul 29; 25(4). PMID: 30054281    Free PMC article.
Highly Cited.
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts.
Christoph Goletz, Timo Lischke, +4 authors, Steffen Goletz.
Front Immunol, 2018 Aug 01; 9. PMID: 30061887    Free PMC article.
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison.
Cancer Discov, 2018 Aug 18; 8(9). PMID: 30115704
Highly Cited. Review.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, +25 authors, Caroline Caramella.
JAMA Oncol, 2018 Sep 08; 4(11). PMID: 30193240    Free PMC article.
Highly Cited.
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
Giuseppe Lo Russo, Massimo Moro, +26 authors, Marina Chiara Garassino.
Clin Cancer Res, 2018 Sep 13; 25(3). PMID: 30206165
Highly Cited.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Marcin Kowanetz, Wei Zou, +27 authors, Priti S Hegde.
Proc Natl Acad Sci U S A, 2018 Oct 10; 115(43). PMID: 30297397    Free PMC article.
Highly Cited.
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Jun Wang, Miguel F Sanmamed, +18 authors, Lieping Chen.
Cell, 2018 Dec 26; 176(1-2). PMID: 30580966    Free PMC article.
Highly Cited.
CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins.
B Huard, P Prigent, +2 authors, F Triebel.
Eur J Immunol, 1995 Sep 01; 25(9). PMID: 7589152
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
S Bolt, E Routledge, +5 authors, H Waldmann.
Eur J Immunol, 1993 Feb 01; 23(2). PMID: 8436176
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.
Y Agata, A Kawasaki, +4 authors, T Honjo.
Int Immunol, 1996 May 01; 8(5). PMID: 8671665
Highly Cited.
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.
H R Koene, M Kleijer, +3 authors, M de Haas.
Blood, 1997 Aug 01; 90(3). PMID: 9242542
Highly Cited.
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.
J Wu, J C Edberg, +5 authors, R P Kimberly.
J Clin Invest, 1997 Sep 01; 100(5). PMID: 9276722    Free PMC article.
Highly Cited.
Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives.
Malgorzata Bobrowicz, Radoslaw Zagozdzon, +3 authors, Magdalena Winiarska.
Cancers (Basel), 2019 Sep 27; 11(10). PMID: 31554169    Free PMC article.
NK Cell-Fc Receptors Advance Tumor Immunotherapy.
Emilio Sanseviero.
J Clin Med, 2019 Oct 17; 8(10). PMID: 31614774    Free PMC article.
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, +3 authors, Suxia Luo.
Mol Cancer, 2019 Nov 07; 18(1). PMID: 31690319    Free PMC article.
Highly Cited. Review.
MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
Jing-Ran Sun, Xiao Zhang, Ya Zhang.
Cell Mol Biol Lett, 2019 Dec 18; 24. PMID: 31844419    Free PMC article.
Tislelizumab: First Approval.
Arnold Lee, Susan J Keam.
Drugs, 2020 Mar 19; 80(6). PMID: 32185681
Tim-3 finds its place in the cancer immunotherapy landscape.
Nandini Acharya, Catherine Sabatos-Peyton, Ana Carrizosa Anderson.
J Immunother Cancer, 2020 Jul 01; 8(1). PMID: 32601081    Free PMC article.
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Josée Golay, Alain E Andrea.
Antibodies (Basel), 2020 May 24; 9(2). PMID: 32443877    Free PMC article.
Pre-existing canine anti-IgG antibodies: implications for immunotherapy, immunogenicity testing and immunoassay analysis.
Daniel Bergman, Camilla Bäckström, +2 authors, Bodil Ström Holst.
Sci Rep, 2020 Jul 31; 10(1). PMID: 32728049    Free PMC article.
Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.
Libin Guo, Ran Wei, Yao Lin, Hang Fai Kwok.
Front Immunol, 2020 Aug 01; 11. PMID: 32733486    Free PMC article.
The Role of IgG4 in the Fine Tuning of Tolerance in IgE-Mediated Allergy and Cancer.
Rodolfo Bianchini, Sophia N Karagiannis, Galateja Jordakieva, Erika Jensen-Jarolim.
Int J Mol Sci, 2020 Jul 28; 21(14). PMID: 32708690    Free PMC article.
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.
Giuseppe Luigi Banna, Ornella Cantale, +4 authors, Alfredo Addeo.
Oncol Rev, 2020 Aug 13; 14(2). PMID: 32782728    Free PMC article.
Targeting phosphatidylserine for Cancer therapy: prospects and challenges.
Wenguang Chang, Hongge Fa, Dandan Xiao, Jianxun Wang.
Theranostics, 2020 Aug 18; 10(20). PMID: 32802188    Free PMC article.
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets.
Emilie Alard, Aura-Bianca Butnariu, +5 authors, Md Zahidul Islam Pranjol.
Cancers (Basel), 2020 Jul 11; 12(7). PMID: 32645977    Free PMC article.
TIGIT in cancer immunotherapy.
Joe-Marc Chauvin, Hassane M Zarour.
J Immunother Cancer, 2020 Sep 10; 8(2). PMID: 32900861    Free PMC article.
Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance.
Charita Furumaya, Paula Martinez-Sanz, +2 authors, Hanke L Matlung.
Front Immunol, 2020 Sep 29; 11. PMID: 32983165    Free PMC article.
A role for the immune system in advanced laryngeal cancer.
Marta Tagliabue, Fausto Maffini, +18 authors, Mohssen Ansarin.
Sci Rep, 2020 Oct 29; 10(1). PMID: 33110100    Free PMC article.
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Simone Camelliti, Valentino Le Noci, +8 authors, Michele Sommariva.
J Exp Clin Cancer Res, 2020 Nov 11; 39(1). PMID: 33168050    Free PMC article.
The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou.
Front Oncol, 2020 Nov 17; 10. PMID: 33194652    Free PMC article.
Efficacy and immune-related adverse event associations in avelumab-treated patients.
Karen Kelly, Juliane Manitz, +8 authors, James L Gulley.
J Immunother Cancer, 2020 Nov 22; 8(2). PMID: 33219092    Free PMC article.
The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
Mazdak Ganjalikhani Hakemi, Morteza Jafarinia, +3 authors, Alexandr V Bazhin.
Front Oncol, 2021 Jan 12; 10. PMID: 33425759    Free PMC article.
Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways.
Jiaxin Liu, Yicheng Cheng, +6 authors, Yong Song.
Signal Transduct Target Ther, 2021 Jan 23; 6(1). PMID: 33479196    Free PMC article.
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
Hope S Rugo, Seock-Ah Im, +28 authors, SOPHIA Study Group.
JAMA Oncol, 2021 Jan 23; 7(4). PMID: 33480963    Free PMC article.
Antibodies to watch in 2021.
Hélène Kaplon, Janice M Reichert.
MAbs, 2021 Jan 19; 13(1). PMID: 33459118    Free PMC article.
IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer.
Galateja Jordakieva, Rodolfo Bianchini, +10 authors, Erika Jensen-Jarolim.
Oncoimmunology, 2021 Feb 26; 10(1). PMID: 33628623    Free PMC article.
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
Jinah Yeo, Minkyung Ko, +2 authors, Hyung-Seung Jin.
Pharmaceuticals (Basel), 2021 Mar 07; 14(3). PMID: 33670993    Free PMC article.
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies.
Boris Grinshpun, Nels Thorsteinson, +4 authors, Yves Fomekong Nanfack.
MAbs, 2021 Jun 13; 13(1). PMID: 34116620    Free PMC article.
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.
Aicha E Quamine, Mallery R Olsen, Monica M Cho, Christian M Capitini.
Cancers (Basel), 2021 Jul 03; 13(11). PMID: 34199783    Free PMC article.
Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy.
Seung Hyun Kang, Chang-Han Lee.
Biotechnol Bioprocess Eng, 2021 Jul 06; 26(3). PMID: 34220207    Free PMC article.
Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity.
Kirsten M Baecher, Mandy L Ford.
Cancer Immunol Immunother, 2021 Jul 10; 70(12). PMID: 34241677
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Firas Hamdan, Erkko Ylösmäki, +18 authors, Vincenzo Cerullo.
J Immunother Cancer, 2021 Aug 08; 9(8). PMID: 34362830    Free PMC article.
Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.
Adrian Elter, Desislava Yanakieva, +4 authors, Harald Kolmar.
Front Immunol, 2021 Aug 21; 12. PMID: 34413859    Free PMC article.
IgG Immune Complexes Inhibit Naïve T Cell Proliferation and Suppress Effector Function in Cytotoxic T Cells.
Wissam Charab, Matthew G Rosenberger, +8 authors, George Georgiou.
Front Immunol, 2021 Aug 28; 12. PMID: 34447380    Free PMC article.
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.
Hulin Jin, Vittorio D'Urso, +10 authors, Ti Cai.
Oncoimmunology, 2021 Sep 07; 10(1). PMID: 34484871    Free PMC article.
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory.
Rūta Veinalde, Gemma Pidelaserra-Martí, +6 authors, Christine E Engeland.
Mol Ther Oncolytics, 2022 Jan 04; 24. PMID: 34977341    Free PMC article.
E3 ubiquitin ligases: styles, structures and functions.
Quan Yang, Jinyao Zhao, Dan Chen, Yang Wang.
Mol Biomed, 2022 Jan 11; 2(1). PMID: 35006464    Free PMC article.
Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Antonino Musolino, William J Gradishar, +4 authors, Mark D Pegram.
J Immunother Cancer, 2022 Jan 08; 10(1). PMID: 34992090    Free PMC article.
Structural and functional characterization of a monoclonal antibody blocking TIGIT.
Bo-Seong Jeong, Hyemi Nam, +10 authors, Byung-Ha Oh.
MAbs, 2022 Jan 30; 14(1). PMID: 35090381    Free PMC article.
Immunotherapies for hepatocellular carcinoma.
Justin K H Liu, Andrew F Irvine, Rebecca L Jones, Adel Samson.
Cancer Med, 2021 Dec 26; 11(3). PMID: 34953051    Free PMC article.
Cancer immunomodulation using bispecific aptamers.
Brian J Thomas, David Porciani, Donald H Burke.
Mol Ther Nucleic Acids, 2022 Feb 11; 27. PMID: 35141049    Free PMC article.
Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Dipti Thakkar, Shalini Paliwal, +9 authors, Jerome D Boyd-Kirkup.
J Immunother Cancer, 2022 Feb 09; 10(2). PMID: 35131861    Free PMC article.
Immune checkpoint blockade in HIV.
Celine Gubser, Chris Chiu, Sharon R Lewin, Thomas A Rasmussen.
EBioMedicine, 2022 Feb 06; 76. PMID: 35123267    Free PMC article.
The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab.
Melissa Neumann, Neal Murphy, Nagashree Seetharamu.
Cancer Med J, 2022 Mar 08; 5(1). PMID: 35253011    Free PMC article.
An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Xin Chen, Liu Xue, +23 authors, Tong Zhang.
Front Immunol, 2022 Mar 12; 13. PMID: 35273608    Free PMC article.
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM.
Sai Kiran Sharma, Maya Suzuki, +8 authors, Jason S Lewis.
J Nucl Med, 2021 Aug 07; 63(4). PMID: 34353869    Free PMC article.
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
Eugene Y Chiang, Ira Mellman.
J Immunother Cancer, 2022 Apr 06; 10(4). PMID: 35379739    Free PMC article.